Anterior horn disorder

This study tests a hexavalent vaccine that protects against six diseases, including polio, but uses a lower dose of the inactivated polio vaccine (IPV). The goal is to see if this reduced-dose version works as well as the standard full-dose vaccine in infants. Around 1,500 health…

This completed study checked the safety of the Hexaxim vaccine in 713 infants aged 2 months and older in South Korea. Researchers tracked side effects like injection site reactions, fever, and crying after routine vaccination. The goal was to confirm the vaccine's safety in every…

This study tested whether giving a booster polio vaccine (sIPV) at the same time as MMR and hepatitis A vaccines is safe and works well in toddlers. About 889 healthy children aged 18 to 22 months who had already received their first polio and MMR shots took part. Researchers che…

This study tested a new vaccine called BK1310 in 370 healthy infants to see if it safely protects against several serious diseases: Hib, diphtheria, pertussis, tetanus, and polio. The vaccine was compared to existing vaccines. The goal was to check how well the infants' immune sy…

This study tested a new vaccine called BK1310 in 267 healthy infants to see if it protects against tetanus, diphtheria, pertussis, polio, and bacterial meningitis as well as existing vaccines. Infants received three doses, and researchers measured their immune responses. The goal…

This completed Phase 3 trial tested a new Sabin strain inactivated polio vaccine (sIPV) in 1200 healthy infants aged 2 months. The study compared the new vaccine to a standard polio vaccine to see if it was safe and triggered a strong immune response. The goal is to offer a more …

This study tested whether giving the polio vaccine (IPV) at the same time as a rotavirus vaccine (Rotarix PCV-free) is safe and works well in healthy Chinese infants aged 6-10 weeks. About 400 infants received the vaccines either together or a few weeks apart. The main goal was t…

This study tested a new combination vaccine called Shan6™, which protects against six diseases (diphtheria, tetanus, whooping cough, hepatitis B, Hib, and polio) in healthy infants and toddlers in Thailand. The trial involved 460 participants and compared Shan6™ to a similar 5-in…

This early-phase study tested the drug baricitinib in 17 people with Alzheimer's disease, ALS, or mild cognitive problems. The goal was to see if the drug reaches the brain and lowers inflammation linked to these diseases. Participants took baricitinib pills for 24 weeks, and res…

This study is testing the drug risdiplam in newborn babies with spinal muscular atrophy (SMA), a serious muscle-weakening disease. The goal is to see how the drug moves through the body and if it is safe for infants under 20 days old. Ten babies will take part, and researchers wi…

This early study tested whether infusing a patient's own regulatory T cells (immune-calming cells) along with interleukin-2 injections is safe for people with ALS. Only 3 participants were enrolled, and the main goal was to check for side effects. The approach aims to slow diseas…

This study tested whether people with ALS or Parkinson's disease, along with healthy volunteers, could follow the MIND diet — a mix of the Mediterranean and DASH diets thought to protect the brain. Over several weeks, 43 participants received a cookbook, educational materials, an…

This study tested the long-term safety of an oral form of edaravone in 124 people with ALS over 96 weeks. Participants took the drug in cycles of 10 days on and 14 days off. The main goal was to see how safe and tolerable the treatment was over time.

This study looked at the long-term safety of an oral form of edaravone in 185 adults with ALS. Participants took the medication for 24 to 48 weeks, and researchers tracked any side effects. The goal was to see if taking the drug by mouth is safe over time for people with this pro…

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier edaravone studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the med…

This study looked at whether a 16-week strength training program can prevent or reduce late effects like muscle loss, heart disease, and diabetes in adults who had a bone marrow transplant as children. 28 survivors and a matched control group participated. The goal was to see if …

This study tested a daily ketone supplement (beta hydroxybutyrate ester) in 81 people with ALS to see if it could slow the disease. The idea is that ketones provide extra energy to cells, which may help counter the energy shortage seen in ALS. Participants took the supplement alo…

This Phase 3 trial tested a stem cell treatment called Lenzumestrocel in 123 people with ALS. The treatment uses the patient's own bone marrow stem cells and is given alongside the standard drug Riluzole. The goal was to see if it could slow the disease and improve survival and f…

This early-phase trial tested whether combining two drugs—abatacept and interleukin-2—is safe for people with ALS. The goal was to boost the body's regulatory T cells, which may help slow disease progression. Only 5 participants were enrolled, and the study focused on safety and …

This trial tested a custom-made drug called nL-TARD-001 in one person with ALS caused by a specific genetic mutation in TARDBP. The drug is an antisense oligonucleotide designed to target the faulty gene. The study measured changes in muscle function, breathing, and thinking over…

This study tested a drug called TPN-101 in 42 people with ALS or frontotemporal dementia caused by a specific gene change (C9orf72). The main goal was to check if the drug is safe and tolerable over 48 weeks. Researchers also looked at how the drug moves in the body and whether i…

This study tested whether deferiprone, a drug that removes excess iron, could safely slow the progression of ALS. Researchers gave the drug to 23 adults with ALS for several months. The goal was to see if reducing iron buildup in the brain might protect nerve cells and delay wors…

This study tested a drug called DNL343 in 249 people with ALS, a serious nerve disease that weakens muscles over time. The goal was to see if DNL343 could slow the disease and help people live longer. The trial used a flexible platform design to test multiple treatments at once.

This phase 3 trial tested a one-time gene therapy called Zolgensma in 22 infants under 6 months old with spinal muscular atrophy (SMA) type 1, a severe muscle-weakening disease. The treatment delivers a working copy of the missing SMN gene via an IV infusion. The main goals were …

This study tested a one-time gene replacement therapy in infants under 6 months old with spinal muscular atrophy (SMA) type 1, a severe muscle-weakening disease. The main goal was to see if treated babies could sit without support for at least 10 seconds by 18 months of age. The …

This study tested a one-time gene replacement therapy in 33 infants under 6 months old with spinal muscular atrophy (SMA) type 1, a severe muscle-weakening disease. The treatment aims to replace the missing SMN1 gene to improve muscle function. Key results showed that many babies…

This study tested a single dose of Zolgensma gene therapy in 30 infants diagnosed with spinal muscular atrophy (SMA) before symptoms appeared. The goal was to see if the treatment helps them reach motor milestones like sitting or standing alone. The therapy delivers a working cop…

This Phase 3 trial tested apitegromab, a drug that blocks a muscle-limiting protein, in 188 nonambulatory children and young adults with later-onset spinal muscular atrophy (SMA types 2 and 3). All participants were already taking standard SMA therapies (nusinersen or risdiplam).…

This study tested a one-time gene therapy called OAV101 (Zolgensma) in 27 children aged 2 to 18 with spinal muscular atrophy (SMA) who had previously stopped taking other SMA medications (Spinraza or Evrysdi). The goal was to see if the treatment is safe and can help maintain or …

This study tested a one-time gene therapy called OAV101 in 126 children aged 2 to 18 with type 2 spinal muscular atrophy (SMA) who had never received other SMA treatments. The therapy was given as a spinal injection and compared to a sham procedure. The goal was to see if it coul…

This Phase 3 trial tested the drug edaravone (MCI-186) in 206 people with ALS. Participants received daily intravenous infusions for 14 days, followed by a rest period, repeated over 24 weeks. The goal was to see if edaravone could slow the decline in physical function compared t…

This study tested the drug edaravone (MCI-186) in 181 people with ALS, a progressive nerve disease. Participants received either edaravone or a placebo through IV infusions over 24 weeks. The goal was to see if edaravone could slow the decline in physical function. Results sugges…

This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. The goal was to see if the drug could slow down the disease compared to a placebo over 24 weeks. The main measure was a scale of daily function. The trial did not show …

This study tested a drug called MCI-186 in 25 people with advanced ALS (severity grade III) to see if it could slow the disease. Participants received either the drug or a placebo daily through an IV for 24 weeks. The main goal was to measure changes in daily function and safety,…

This completed Phase 2/3 trial tested whether deferiprone, a drug that removes excess iron from the body, can slow the progression of ALS (Lou Gehrig's disease). 372 people with early-stage ALS took either deferiprone or a placebo for 12 months. The study measured changes in phys…

This phase 2 trial tested whether low-dose interleukin-2 (IL-2) can help control nerve inflammation in people newly diagnosed with ALS. Over 18 months, 304 participants received either IL-2 or a placebo, alongside standard riluzole treatment. The goal was to see if boosting regul…

This phase II study tested whether low doses of interleukin-2 (IL-2) can safely boost regulatory T cells in people with amyotrophic lateral sclerosis (ALS). 36 participants received either IL-2 or a placebo for five days. The goal was to see if this immune-modulating approach cou…

This completed Phase 2/3 trial tested an oral drug called ABBV-CLS-7262 in 310 people with ALS. Participants took the drug or a placebo once daily for 24 weeks. The study measured how fast the disease progressed and survival rates. The goal was to see if the drug could slow ALS a…

This study tested a drug called nusinersen (Spinraza) in 25 infants who have a genetic diagnosis of spinal muscular atrophy (SMA) but no symptoms yet. The drug is given through a spinal injection to help delay or prevent the need for breathing support or early death. The goal was…

This study tested the drug nusinersen (Spinraza) in 46 children under 3 years old with spinal muscular atrophy (SMA) who had previously received gene therapy but still had health challenges. The goal was to see if adding nusinersen could improve their muscle and movement abilitie…

This phase 2 trial tested whether adding IFB-088 to standard riluzole treatment is safe and effective for people with bulbar-onset ALS (a form that first affects speech and swallowing). 51 participants received either IFB-088 plus riluzole or a placebo plus riluzole for 6 months.…

This study looked at the long-term safety of an experimental drug called Engensis for people with ALS (Lou Gehrig's disease). Eight people who had already received Engensis in an earlier study were followed for 6 more months. Researchers tracked side effects to see if the drug re…

This completed Phase 2 trial tested a combination of liposomed curcumin (from turmeric) and resveratrol (from grapes) plus a drug called G04CB02 in 90 people with ALS. The goal was to see if this mix could improve muscle function, thinking, and inflammation over 2 months of treat…

This study tested a drug called troriluzole in 141 adults with spinocerebellar ataxia, a rare disease that affects balance and coordination. Participants took either the drug or a placebo daily for 8 weeks. The main goal was to see if troriluzole could improve symptoms like walki…

This study tested the safety and drug levels of risdiplam, a daily oral medication, in 174 adults and children with spinal muscular atrophy (SMA). Participants had previously received other SMA treatments. The main goals were to check for side effects and measure how the drug mov…

This completed Phase 2 pilot trial tested whether personalized supplements could slow the progression of ALS. Researchers used a genetic analysis platform to sort 50 participants into four disease categories—neuroinflammation, oxidative stress, impaired autophagy, or mitochondria…

This phase IIb trial tested PrimeC, a combination of two common drugs (ciprofloxacin and celecoxib), in 69 people with ALS. Participants took PrimeC or a placebo for 6 months, followed by a 12-month open-label extension where everyone received PrimeC. The study measured safety, s…

This phase 1 study tested a single dose of the experimental drug QRL-101 in 12 people with ALS. The main goals were to see how the drug moves through the body and whether it is safe. Participants received either QRL-101 or a placebo, and researchers monitored side effects and dru…

This study tested a new PET imaging tracer to see if it can safely show signs of ALS in the body. Eight people (some healthy, some with ALS) received the tracer and were scanned. The goal was to check safety and how the tracer spreads, which could lead to earlier diagnosis and be…

This study looked at whether chemicals in tears and eye surface cells can help diagnose amyotrophic lateral sclerosis (ALS) or predict how the disease will progress. Researchers collected tear samples and performed eye exams on 55 people with ALS and healthy controls. The goal wa…

This completed study looked at how well a camera test called FEES (flexible endoscopic evaluation of swallowing) can detect and track swallowing problems in people with spinal muscular atrophy (SMA). Researchers studied 79 SMA patients of different types and ages, using several s…

This study aimed to develop a non-invasive prenatal test using fetal cells from a mother's blood to detect triplet repeat diseases like Huntington's disease, Fragile X syndrome, and certain types of muscular dystrophy and ataxia. Researchers enrolled 60 pregnant women at risk and…

This trial evaluates whether a hospital-based remedial vaccination strategy can improve Tdap-IPV (tetanus, diphtheria, pertussis, polio) vaccination rates in adults aged 65 and older in the Sarthe region of France. Participants are randomly assigned to receive either the remedial…

This study tested whether a polio vaccine (sIPV) is still effective when given at the same time as other routine vaccines for infants, like those for pneumonia, diphtheria, tetanus, and whooping cough. About 1,400 babies in Bangladesh and Pakistan received the polio vaccine eithe…

This study tests whether a wheelchair-mounted robotic arm called Jaco helps people with tetraplegia perform daily tasks like grasping and reaching at home. Participants use the device for two months after training. Researchers measure changes in performance and satisfaction with …

This study tested whether people with ALS can start using a breathing machine at home instead of in the hospital. 46 patients were randomly assigned to start either at home with remote monitoring or in the hospital. The goal was to see if home initiation works just as well, measu…

This pilot study tested whether adding a vibrating chest vest to a standard cough-assist machine could reduce lung infections and hospital stays in people with ALS who use breathing support. Fourteen patients were randomly assigned to use either the vest plus cough assist or the …

This study tested a 12-week online peer support programme for family caregivers of people with motor neurone disease who are becoming dependent on breathing or feeding technology. The programme included private messaging, weekly chats, a discussion forum, and resources. Researche…

This study tested an experimental drug called NMD670 in 52 adults with type 3 spinal muscular atrophy who can still walk. The goal was to see if the drug helps them walk farther in 6 minutes and improves muscle strength compared to a placebo. The trial is now complete, and result…

This study tested a portable knee training device in 13 children aged 6-12 with spinal muscular atrophy (SMA). The goal was to see if regular exercise with the device could improve leg muscle strength and function. Researchers measured muscle size, strength, and nerve activity ov…

This study tested a 'Digital Strolling' program where people with severe mobility impairment use a virtual reality headset to walk in a digital world. 24 participants either used the VR walking or watched walking videos for 10 days. The goal was to see if this approach could impr…

This study tested whether virtual reality (using Xbox Kinect) or biofeedback training could improve motor function and balance in 24 children with neuromuscular diseases like Duchenne muscular dystrophy and spinal muscular atrophy. Participants were split into three groups: VR tr…

This completed trial from Harvard University tested whether an online mindfulness program and social community could improve quality of life for 100 people with ALS and their primary caregivers. Participants used a three-week e-learning program with cognitive exercises and videos…

This Phase 3 study tested whether injections of MYOBLOC (a botulinum toxin type B) into the salivary glands can safely reduce troublesome drooling in adults. 187 participants received either MYOBLOC or a placebo. The main goals were to measure changes in saliva flow and overall i…

This study tested whether adding transcranial magnetic stimulation (TMS) to standard exercise can reduce fatigue, pain, and improve walking in people with postpolio syndrome. 26 adults who had polio earlier in life and now have new symptoms took part. Half got TMS plus exercise, …

This small pilot study tested whether a temporary spinal cord stimulator (like a pacemaker for the spine) could help people with spinal muscular atrophy types 3 and 4 move their legs better. Three adults who could stand independently received the implant for up to 29 days. The go…

This study looked at whether a moderate-intensity breathing exercise program is safe and doable for people with ALS. Nine adults with ALS did four 3-week cycles of respiratory muscle training at home, with weekly check-ins via video call. The main goal was to see if participants …

This study tested an online insomnia treatment program for adult survivors of childhood cancer. Over 1,500 survivors participated, using a web-based program that teaches healthy sleep habits and cognitive behavioral techniques. The goal was to see if improving sleep could also bo…

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS). Participants received either engensis or a placebo injection into their muscles. The main goal was to check for side effects, while also exploring effects o…

This early-phase trial tested whether a gene therapy called VM202 is safe when injected into muscles of 18 people with ALS. The study focused on side effects over 9 months, not on whether the treatment improves symptoms. All participants had ALS for less than 2 years and had at l…

This study follows about 74 adults with ALS who have already decided to take the drug Edaravone (Radicava). Researchers collect blood and urine samples over 24 weeks to measure various biomarkers—molecules that might show how the drug affects oxidative stress, inflammation, and n…

This study is testing whether a smartphone app can reliably track speech and swallowing problems in people with ALS. Participants will record their voice and swallowing sounds at home each week using the app. The goal is to see if this remote monitoring is feasible and accurate c…

This study tests whether wearable sensors and digital home tasks can track changes in movement, speech, and falls in people with ALS. About 20 participants will wear neck and wrist sensors and complete speech and handwriting tests over 48 weeks. The goal is to see if these digita…

This study explores whether digital tools on a tablet can measure changes in speech and handwriting in people with motor neuron diseases like ALS. Participants complete a single session of speaking and tracing tasks. Researchers compare results between patients and healthy contro…

This study followed 50 adults with a C9ORF72 gene mutation that can cause ALS or frontotemporal dementia. Over three years, researchers measured changes in strength, thinking, memory, and behavior using brain scans, spinal fluid tests, and other assessments. The goal was to under…

This study looks at whether a French version of the SMAFRS questionnaire gives reliable results when used twice in adults with spinal muscular atrophy (SMA). About 60 participants will fill out the questionnaire during a routine visit and again 15 days later. No treatment is give…

This study tested whether a brain-computer interface (BCI) device is ready for commercial use to help people with minimal movement communicate. Researchers worked with 8 device users, plus speech therapists and support staff, to evaluate how well the device worked at home. The go…

This study looks at how ALS (Lou Gehrig's disease) affects social thinking, like recognizing emotions in faces and voices. Researchers will compare 74 ALS patients to healthy volunteers using video-based tests. The goal is to better understand these challenges, which can impact d…

This study looked at whether vitamin D levels in the blood are linked to how fast ALS (Lou Gehrig's disease) gets worse. Researchers measured vitamin D in 127 people with ALS and tracked their motor decline, breathing, and weight loss. No treatment was given—the goal was simply t…

This early-stage study looked at how a single dose of oral edaravone moves through the bodies of 9 Japanese adults with ALS. The main goal was to measure drug levels in the blood and urine, not to test if it helps symptoms. Researchers also tracked any side effects. The study is …

This early-stage study looked at how the body handles a single dose of oral edaravone in 6 Japanese ALS patients who have a feeding tube (gastrostomy). The goal was to measure drug levels in the blood and urine, not to test if it works. No treatment benefit was evaluated.

This study looked at how many people with cirrhosis in French general hospitals were vaccinated against diseases like hepatitis, flu, and COVID-19. Researchers surveyed 742 patients to see if they were up to date on their shots. The goal was to find gaps in vaccination coverage s…

This study tested whether a telehealth system could help people with motor neurone disease (MND) receive specialist care from home, avoiding long trips to the clinic. It involved 40 patients and their caregivers, with half using the system for up to 18 months. The goal was to see…

This completed study looked at how the drug deferiprone affects blood cells from 90 people with Parkinson's disease, ALS, or healthy volunteers. Researchers measured markers of oxidative stress and iron levels in the lab. The goal was to better understand these diseases, not to t…

This completed study of 500 people with ALS (Lou Gehrig's disease) aimed to find biological signs, or biomarkers, that can predict how the disease will progress. Researchers collected clinical, imaging, and lab data to better understand different forms of ALS. The goal is to help…

This completed study looked at how muscle oxygen levels change during exercise in people with various neuromuscular diseases compared to healthy volunteers. Seventeen participants did a knee-extension exercise while a device measured muscle oxygen. The goal was to understand diff…

This study analyzed medical records of 213 children with spinal muscular atrophy (SMA) in the Czech and Slovak Republics. Researchers looked at what treatments were used and how the children's motor skills, breathing, and feeding changed over time. The goal was to understand real…

This early study tested whether a special ultrasound technique could safely open the blood-brain barrier in the motor area of the brain in 4 people with ALS. The goal was to see if the procedure was safe and possible, not to treat the disease. Researchers measured side effects an…

This study looked at 67 adults with spinal muscular atrophy (SMA) types 2 and 3 to see if special electrical tests (MUNE and CMAP) can track nerve loss over time. The goal was to find better ways to measure how the disease changes, not to test a treatment. Participants had geneti…

This study looked at 18 adults with spinal muscular atrophy (SMA) who had taken the oral medication risdiplam for at least one year. Researchers measured how well nerves and muscles communicate by using electrical stimulation tests. The goal was to see if risdiplam improves these…

This study tested a new way to control a robotic arm mounted on a power wheelchair. The arm uses a camera to help guide movements, making tasks like grabbing a drink easier. 21 adults who use power wheelchairs and have trouble with everyday tasks took part. They compared the new …

This study analyzed health records of nearly 5,000 people with spinal muscular atrophy (SMA) to see how well three approved treatments work in everyday medical practice. Researchers looked at complications, medical equipment use, and hospital visits before and after starting each…

This study analyzed insurance claims from over 4,000 people with spinal muscular atrophy to see how three approved treatments (Zolgensma, Spinraza, and Evrysdi) are actually used in daily practice and what they cost over time. Researchers looked at dosing patterns, yearly drug co…

This study tested whether advanced MRI scans can find new biomarkers for amyotrophic lateral sclerosis (ALS), a fast-progressing nerve disease. Researchers used high-field and very-high-field MRI to look at the brain, spinal cord, and muscles of 22 ALS patients over six months. T…

This study looked at how nerves in the spine work in people recently diagnosed with ALS compared to healthy volunteers. The goal was to find specific electrical signals that could help doctors understand the disease better and track its progress. 101 participants took part in tes…

This completed study looked at how metabolism differs in people with ALS. Researchers took blood and skin samples from 9 patients to analyze molecules and genes. The goal was to better understand the disease, not to test a treatment.

This study aimed to find biological markers (biomarkers) in muscle, blood, and cells to help diagnose amyotrophic lateral sclerosis (ALS) earlier and understand the disease better. Researchers analyzed samples from 37 adults with ALS using advanced techniques to look at molecules…

This study looked back at 80 children with spinal muscular atrophy (SMA) types II and III to see how using braces (orthoses) helped them sit, stand, and walk. Researchers recorded when and how often children achieved these milestones and what types of braces they used. The goal w…

This completed Phase 1 trial tested the safety and how the body absorbs VRG50635 in 22 healthy adults aged 19 to 55. Participants received either the drug or a placebo. The study focused on side effects and drug levels in the blood, not on treating any disease.

This completed study looked at 60 people — 30 with ALS and 30 healthy volunteers — to measure immune system and nerve damage markers in their blood and spinal fluid. The goal was to better understand the role of a specific immune pathway (IFN-alpha) in ALS. By linking these marke…

This completed study looked at why people with spinal muscular atrophy (SMA) often feel very tired and have trouble exercising. Researchers tested 34 ambulatory SMA patients who were already on standard treatments (risdiplam or nusinersen) for at least six months. Participants di…

This completed study looked for genetic and environmental factors that increase the risk of developing Parkinson's disease. Researchers compared DNA and lifestyle data from over 2,200 people, including Parkinson's patients, people with related brain diseases, and healthy voluntee…

This completed study looked at whether it is practical and acceptable to screen all newborns for spinal muscular atrophy (SMA), a rare genetic disease that causes muscle weakness and can be fatal if not treated early. Over 33,000 babies were screened using a simple blood spot tes…

This completed study looked at genetic differences in vitamin D processing and action in 400 people with ALS and 400 healthy controls. Researchers analyzed DNA samples to find variations in eight specific genes. The goal was to better understand the biology of ALS, not to test a …

This study looked at how amyotrophic lateral sclerosis (ALS) affects the brain's ability to process touch and other sensations, even when patients don't notice problems. Researchers used brain imaging and electrical recordings to compare 52 people with ALS and healthy volunteers.…

This study interviewed 15 people with ALS to learn about unpleasant sensations or pain they experienced during clinical trial procedures. The goal was to identify which procedures cause discomfort and how long it lasts, so future trials can be more patient-friendly. Researchers a…

This completed study looked at 40 people with spinocerebellar ataxia types 2 and 7, a rare brain disease that affects movement. Researchers used MRI scans and lumbar punctures over one year to track changes in the brain and body. The goal was to find reliable markers that could b…

This study looks at how ALS affects the way people start walking and keep their balance. Researchers will compare ALS patients with and without balance issues, plus healthy volunteers, using walking tests and brain scans. The goal is to find out if certain brain changes cause wal…

This small study tested whether briefly restricting blood flow to one arm (called remote ischemic conditioning, or RIC) could improve hand function in people with spinal cord injury or ALS. Participants did hand exercises while receiving either active RIC or a sham version. The g…

This study first surveyed 888 nurses across Spain and found that over 70% lacked adequate knowledge of advanced life support (ALS). Researchers then tested a training program with 38 nurses in one region, combining online materials with a four-hour hands-on workshop. After the tr…

This completed study looked at 44 people with ALS and healthy controls to see how gut bacteria and short-chain fatty acids change over time. Researchers also tested whether a 6-month Mediterranean diet could shift these levels. The goal was to better understand the gut-brain conn…

This study looked at 70 elderly women with long-term non-specific low back pain to see how their balance relates to disability, fear of falling, and social participation. Researchers measured balance, disability, and community involvement. The goal is to better understand these c…

This study looked at the quality of supportive and palliative care for infants under one year old with spinal muscular atrophy (SMA) type 1, a severe genetic muscle disease. Researchers followed 39 infants and asked families to keep a diary about care. One year after the child's …